GRIFOLS | GRF - Cash And Equivalent



GRIFOLS reported EUR558.69M in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
Alcon AG USD 1.41B 4M Jun/2025
Almirall EUR 374.4M 2.7M Mar/2025
Amadeus IT EUR 1.49B 444.3M Mar/2025
Amarin USD 119.52M 1.51M Mar/2025
argenx SE 2.09B 586.04M Jun/2025
AstraZeneca USD 7.06B 1.83B Jun/2025
Bayer EUR 4.56B 542M Jun/2025
Cie Automotive EUR 486.62M 9.22M Dec/2024
Demant 1.14B 30M Jun/2025
Ence Energia y Celulosa EUR 318.8M 79.9M Sep/2024
Essilor EUR 2.25B 86M Dec/2024
Ferrovial EUR 4.81B 1.17B Dec/2024
Fresenius EUR 1.23B 1.16B Jun/2025
Fresenius Medical Care EUR 1.72B 644.08M Jun/2025
Galapagos EUR 108.07M 43.83M Mar/2025
Genmab DKK 1.3B 323M Jun/2025
GlaxoSmithKline GBP 3.6B 865M Jun/2025
GRIFOLS EUR 558.69M 194.13M Jun/2025
Hikma Pharmaceutical USD 188M 188M Dec/2024
Inditex EUR 5.97B 409M Apr/2025
Merck EUR 1.17B 161M Jun/2025
Novartis USD 6.66B 410M Jun/2025
Philips EUR 1.82B 629M Jun/2025
Roche Holding CHF 6.98B 2.15B Dec/2024
Sanofi 15.36B 7.37B Jun/2025
UCB EUR 1.57B 1.14B Dec/2024
Viscofan EUR 46.53M 24.9M Jun/2025